Aurinia receives EU marketing authorization for LUPKYNIS; director Walbert resigns

Aurinia Pharmaceuticals Inc.

EC grants marketing authorization for LUPKYNIS (voclosporin) to treat active lupus nephritis in EU, Iceland, Liechtenstein, Norway, and Northern Ireland.
Aurinia to receive $30M milestone payment from Otsuka for EC approval; cash within 30 days of invoicing.
Director Timothy P. Walbert resigns from Board effective Sept. 19, 2022; no disagreement with company.
LUPKYNIS previously received FDA approval in Jan. 2021 for same indication.

item 7.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Timothy P. Walbert

Director

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2022-09-19
Filed: September 19, 2022, 7:59 PM ET

On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy P. Walbert resigned as Director at Aurinia Pharmaceuticals Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-025148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.